8-K: Tharimmune Faces Nasdaq Non-Compliance on Board Independence

Tharimmune, Inc. received a Nasdaq notification for non-compliance with board independence rules but expects to regain compliance after a special shareholder meeting.

Summary

• Tharimmune, Inc. (THAR) received a notification from The Nasdaq Stock Market LLC on January 9, 2026, regarding non-compliance with Listing Rule 5605.
• Rule 5605 requires a majority of the Board of Directors to be comprised of independent directors.
• The non-compliance resulted from the resignations of Nancy Davis and Sanam Parikh, effective November 6, 2025, and the subsequent election of Mark Wendland, leaving a vacancy and an insufficient number of independent directors.
• The company has been granted a cure period until the earlier of its next annual shareholders meeting or November 6, 2026, or May 5, 2026, if the annual meeting is before that date.
• The company plans to cure this non-compliance by seeking shareholder approval to elect two additional independent directors at a special meeting on January 30, 2026.

Sentiment

Score: 4

Explanation: The company is in non-compliance with a key Nasdaq listing rule, which is a negative event. However, the company has a clear, immediate plan to rectify the situation and expects to regain compliance, mitigating the severity of the initial negative news.

Positives

• The company has a clear plan to regain compliance with Nasdaq Listing Rule 5605.
• A cure period has been granted by Nasdaq, providing time to address the non-compliance.
• The company expects to achieve compliance after the special shareholders meeting on January 30, 2026.

Negatives

• Tharimmune, Inc. is currently non-compliant with Nasdaq Listing Rule 5605 regarding board independence.
• The non-compliance was triggered by the resignations of two board members, Nancy Davis and Sanam Parikh.

Risks

• Failure to regain compliance with Nasdaq Listing Rule 5605 could lead to delisting from The Nasdaq Stock Market LLC.
• Actual results may differ materially from forward-looking statements due to numerous risks and uncertainties, including those found in the company's periodic reports.

Future Outlook

The company expects to cure the non-compliance with Nasdaq listing standards after the special meeting of shareholders on January 30, 2026, at which it will seek approval to elect two additional independent directors. It anticipates that a majority of its Board will be independent following this meeting.

Management Comments

• "The Company expects to cure this non-compliance after the special meeting of shareholders on January 30, 2026, at which it will seek shareholders approval to elect two additional independent directors to the Board."
• "The Company expects that a majority of its Board will be independent after the special meeting."

Industry Context

This announcement highlights the ongoing importance of corporate governance and board independence for publicly traded companies, particularly in meeting exchange listing requirements. Maintaining a majority of independent directors is a standard practice aimed at ensuring objective oversight and protecting shareholder interests, a trend consistently emphasized by regulatory bodies like the SEC and stock exchanges.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potential risk of delisting if compliance is not regained, but the company's plan aims to mitigate this. Shareholder approval is required for new director elections.
• Management/Board: Increased focus on corporate governance and board composition to ensure compliance.

Next Steps

• Hold a special meeting of shareholders on January 30, 2026.
• Seek shareholder approval to elect two additional independent directors to the Board.
• Regain compliance with Nasdaq Listing Rule 5605.

Key Dates

Recommendation

While the non-compliance with Nasdaq rules is a negative event, the company has a clear and immediate plan to rectify the situation, including a special shareholder meeting to elect new independent directors. The expectation to regain compliance within the cure period suggests that the issue is manageable. Investors should hold to see the successful execution of the plan, as the underlying business operations are not directly impacted by this governance issue, and the risk of delisting appears to be actively addressed.

Keywords

Tharimmune, THAR, Nasdaq, Listing Rule 5605, Board of Directors, Independent Directors, Corporate Governance, SEC Filing, 8-K, Compliance